Exploring Tetrahydroisoquinoline (THIQ) Scaffold as Therapeutic Modulators of Sigma Receptors.

Dikshita Lama, Albert Michael Crider, Marcelo J Nieto

Abstract readReview

In one paragraph

Review in Mini reviews in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dikshita LamaDepartment of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, 200 University Park Dr. Suite 220, Edwardsville, IL, 61025, United States.ORCID 0009-0000-8752-4058

Albert Michael CriderDepartment of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, 200 University Park Dr. Suite 220, Edwardsville, IL, 61025, United States.

Marcelo J NietoDepartment of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, 200 University Park Dr. Suite 220, Edwardsville, IL, 61025, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sigma receptors (σRs), comprising σ1 and σ2 subtypes, are versatile pharmacological targets with significant roles in cancer, neurodegeneration, and psychiatric disorders. The tetrahydroisoquinoline (THIQ) scaffold, a core structure in many biologically active compounds, has garnered attention as a versatile platform for designing σRs ligands. THIQ-based compounds exhibit potent σRs binding affinity, leading to therapeutic effects ranging from neuroprotection to antitumor activity. This mini-review explores the structural features of THIQ ligands, their interaction with σRs, and their therapeutic implications. Challenges and future prospects for THIQ derivatives in σRs research are also discussed.

Indexed as

Antineoplastic AgentsNeuroprotective AgentsReceptors, sigmaTetrahydroisoquinolinesAnimalsHumansLigandsMolecular StructureNeoplasms1,2,3,4-tetrahydroisoquinolineAntineoplastic AgentsLigandsNeuroprotective AgentsReceptors, sigmaTetrahydroisoquinolinespharmacophore.SARSigma receptorstetrahydroisoquinolineσ1Rσ2R

Identifiers

PMID40698690

DOI10.1016/j.bmc.2015.02.012

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.